文献速递肝病消化道肿瘤与早癌

人和小鼠肝细胞AXIN缺陷在无β-catenin激活情况下诱导肝细胞癌

AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
PubMed 文献 · J Hepatol · 2018-03-07

研究评估两个独立人肝细胞癌数据集中23个β-catenin靶基因程序的表达,并在两种工程小鼠模型中建模Axin1功能缺失肿瘤发生及基因表达谱分析。基于基因表达定义β-catenin程序激活的强、弱或无激活三个水平,超过80%的CTNNB1突变肿瘤位于强或弱激活程序,而大多数AXIN1突变肿瘤(>70%)位于无激活亚组。小鼠肝细胞特异性AXIN1缺失在无β-catenin诱导情况下发生肝细胞癌,并定义人类和小鼠AXIN1突变肝细胞癌共有的329基因特征,富集Notch和YAP致癌特征。

要点

  • 超过80%的CTNNB1突变肿瘤位于β-catenin程序强或弱激活组。
  • 大多数AXIN1突变肿瘤(>70%)位于β-catenin程序无激活亚组。
  • AXIN1突变肝细胞癌发生不依赖Wnt/β-catenin通路,涉及Notch和YAP通路。

核心结论

  • AXIN1突变肝细胞癌的发生独立于Wnt/β-catenin通路,并涉及Notch和YAP通路;这些通路构成治疗AXIN1突变所致肝细胞癌的潜在有趣靶点。

研究设计与样本

  • 评估两个独立人肝细胞癌数据集中23个β-catenin靶基因程序的表达。
  • 在两种工程小鼠模型中建模Axin1功能缺失肿瘤发生并进行基因表达谱分析。

主要发现

  • 基于基因表达定义β-catenin程序激活的三个水平:强、弱或无激活。
  • 超过80%的CTNNB1突变肿瘤位于强或弱激活程序。
  • 大多数AXIN1突变肿瘤(>70%)位于无激活亚组。
  • 肝细胞特异性AXIN1缺失小鼠在无β-catenin诱导情况下发生肝细胞癌。
  • 定义人类和小鼠AXIN1突变肝细胞癌共有的329基因特征,高度富集Notch和YAP致癌特征。

关键数值与推荐

  • CTNNB1突变肿瘤中超过80%位于β-catenin程序强或弱激活组。
  • AXIN1突变肿瘤中超过70%位于β-catenin程序无激活亚组。
  • AXIN1突变肝细胞癌共有329基因特征,高度富集Notch和YAP致癌特征。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The Wnt/β-catenin pathway is the most frequently deregulated pathway in hepatocellular carcinoma (HCC). Inactivating mutations of the gene encoding AXIN1, a known negative regulator of the Wnt/β-catenin signaling pathway, are observed in about 10% of HCCs. Whole-genome studies usually place HCC with AXIN1 mutations and CTNNB1 mutations in the group of tumors with Wnt/β-catenin activated program. However, it has been shown that HCCs with activating CTNNB1 mutations form a group of HCCs, with a different histology, prognosis and genomic signature to those with inactivating biallelic AXIN1 mutations. We aimed to elucidate the relationship between CTNNB1 mutations, AXIN1 mutations and the activation level of the Wnt/β-catenin program. METHODS: We evaluated two independent human HCC datasets for the expression of a 23-β-catenin target genes program. We modeled Axin1 loss of function tumorigenesis in two engineered mouse models and performed gene expression profiling. RESULTS: Based on gene expression, we defined three levels of β-catenin program activation: strong, weak or no activation. While more than 80% CTNNB1-mutated tumors were found in the strong or in the weak activation program, most of the AXIN1-mutated tumors (>70%) were found in the subgroup with no activation. We validated this result by demonstrating that mice with a hepatocyte specific AXIN1 deletion developed HCC in the absence of β-catenin induction. We defined a 329-gene signature common in human and mouse AXIN1 mutated HCC that is highly enriched in Notch and YAP oncogenic signatures. CONCLUSIONS: AXIN1-mutated HCCs occur independently of the Wnt/β-catenin pathway and involve Notch and YAP pathways. These pathways constitute potentially interesting targets for the treatment of HCC caused by AXIN1 mutations. LAY SUMMARY: Liver cancer has a poor prognosis. Defining the molecular pathways involved is important for developing new therapeutic approaches. The Wnt/β-catenin pathway is the most frequently deregulated pathway in hepatocellular carcinoma (HCC). Mutations of AXIN1, a member of this pathway, represent about 10% of HCC mutations. Using both human HCC collections and engineered mouse models of liver cancers with AXIN1 mutation or deletion, we defined a common signature of liver tumors mutated for AXIN1 and demonstrate that these tumors occur independently of the activation of the Wnt/β-catenin pathway.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Abitbol S, Dahmani R, Coulouarn C, et al. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation. J Hepatol. 2018. PMID: 29525529. doi:10.1016/j.jhep.2017.12.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。